EP4691459A1 — Combination formulation comprising sacubitril-valsartan and sglt-2 inhibitor having improved stability and dissolution rate
Assigned to Hanmi Pharmaceutical Co Ltd · Expires 2026-02-11 · 0y expired
What this patent protects
The present invention relates to a pharmaceutical combination formulation which has a synergistic effect in the treatment of heart failure by containing both sacubitril-valsartan and an SGLT-2 inhibitor as active ingredients, and at the same time, ensures bioequivalence between t…
USPTO Abstract
The present invention relates to a pharmaceutical combination formulation which has a synergistic effect in the treatment of heart failure by containing both sacubitril-valsartan and an SGLT-2 inhibitor as active ingredients, and at the same time, ensures bioequivalence between the drugs because the effect of one drug on the dissolution of the other drug is minimized. In addition, the generation of impurities in the pharmaceutical combination formulation is inhibited, and thus the stability of the active ingredients is also excellent.
Drugs covered by this patent
- Farxiga (DAPAGLIFLOZIN) · AstraZeneca
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.